|
SI2049664T1
(sl)
|
2006-08-11 |
2012-04-30 |
Prosensa Technologies Bv |
Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev
|
|
ES2639852T3
(es)
|
2007-10-26 |
2017-10-30 |
Academisch Ziekenhuis Leiden |
Medios y métodos para contrarrestar los trastornos musculares
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
EP2595663A4
(en)
|
2010-07-19 |
2014-03-05 |
Isis Pharmaceuticals Inc |
MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION
|
|
CA2817256A1
(en)
|
2010-11-12 |
2012-05-18 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
US8569254B2
(en)
*
|
2010-12-10 |
2013-10-29 |
National Yang Ming University |
Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
|
|
AU2012246822B2
(en)
*
|
2011-04-22 |
2017-05-25 |
Biomarin Technologies B.V. |
New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1)
|
|
WO2013033223A1
(en)
|
2011-08-29 |
2013-03-07 |
Isis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
NZ627896A
(en)
|
2012-01-27 |
2016-11-25 |
Biomarin Technologies B V |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
WO2013120003A1
(en)
|
2012-02-08 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
|
LT2841578T
(lt)
*
|
2012-04-23 |
2017-09-25 |
Biomarin Technologies B.V. |
Rnr moduliuojantys oligonukleotidai su pagerintomis savybėmis, skirti neuromuskulinių susirgimų gydymui
|
|
AU2013262699A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating ATP2A2 expression
|
|
EA201492122A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии utrn
|
|
SG11201407483YA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating smn gene family expression
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
|
US10029916B2
(en)
|
2012-06-22 |
2018-07-24 |
C3Nano Inc. |
Metal nanowire networks and transparent conductive material
|
|
EP2870246B1
(en)
|
2012-07-03 |
2019-09-11 |
BioMarin Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
RS54944B1
(sr)
|
2012-07-12 |
2016-11-30 |
Proqr Therapeutics Ii Bv |
Oligonukleotidi za pravljenje promena u sekvencama ciljanih rnk molekula prisutnih u živoj ćeliji
|
|
US10020807B2
(en)
|
2013-02-26 |
2018-07-10 |
C3Nano Inc. |
Fused metal nanostructured networks, fusing solutions with reducing agents and methods for forming metal networks
|
|
CA2917229A1
(en)
*
|
2013-07-02 |
2015-01-08 |
Isis Pharmaceuticals, Inc. |
Modulators of growth hormone receptor
|
|
US10435430B2
(en)
|
2013-07-31 |
2019-10-08 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
EP3119888B1
(en)
|
2014-03-19 |
2021-07-28 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
BR112016022742B1
(pt)
|
2014-05-01 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
Composto químico, composição compreendendo o composto e uso dos mesmos
|
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
|
WO2016149455A2
(en)
|
2015-03-17 |
2016-09-22 |
The General Hospital Corporation |
The rna interactome of polycomb repressive complex 1 (prc1)
|
|
SG11201707513QA
(en)
|
2015-05-29 |
2017-10-30 |
Univ Leland Stanford Junior |
Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
|
|
KR102599157B1
(ko)
*
|
2015-08-14 |
2023-11-06 |
메르크 파텐트 게엠베하 |
유기 전계발광 소자용 페녹사진 유도체
|
|
IL294124B2
(en)
|
2015-12-10 |
2024-02-01 |
Ptc Therapeutics Inc |
Methods for treating huntington's disease
|
|
AU2016381174A1
(en)
|
2015-12-31 |
2018-05-31 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing Ataxin-2 expression
|
|
MX2018016253A
(es)
*
|
2016-07-05 |
2019-09-09 |
Biomarin Tech Bv |
Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos.
|
|
JOP20190104A1
(ar)
*
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
ES3038159T3
(en)
|
2016-11-16 |
2025-10-09 |
Academisch Ziekenhuis Leiden |
Substances for targeting various selected organs or tissues
|
|
CA3043768A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11268093B2
(en)
|
2017-01-03 |
2022-03-08 |
Rula Zain-Luqman |
Therapeutic method for huntington's disease
|
|
WO2018165541A1
(en)
*
|
2017-03-10 |
2018-09-13 |
The Board Of Regents Of The University Of Texas System |
Treatment of fuchs' endothelial corneal dystrophy
|
|
US11407753B2
(en)
|
2017-06-05 |
2022-08-09 |
Ptc Therapeutics, Inc. |
Compounds for treating Huntington's disease
|
|
WO2019005993A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
METHODS OF TREATING HUNTINGTON'S DISEASE
|
|
US11382918B2
(en)
|
2017-06-28 |
2022-07-12 |
Ptc Therapeutics, Inc. |
Methods for treating Huntington's Disease
|
|
EP3808849A1
(en)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
MX2020009957A
(es)
|
2018-03-27 |
2021-01-15 |
Ptc Therapeutics Inc |
Compuestos para el tratamiento de enfermedad de hungtinton.
|
|
PL3814357T3
(pl)
|
2018-06-27 |
2024-09-16 |
Ptc Therapeutics, Inc. |
Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
|
|
EP3814345B8
(en)
|
2018-06-27 |
2024-10-30 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
AR115847A1
(es)
|
2018-07-25 |
2021-03-03 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de la atxn2
|
|
SG11202103938UA
(en)
|
2018-11-02 |
2021-05-28 |
Biomarin Tech Bv |
Bispecific antisense oligonucleotides for dystrophin exon skipping
|
|
WO2020231977A1
(en)
|
2019-05-13 |
2020-11-19 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
AU2020377204A1
(en)
|
2019-11-01 |
2022-06-02 |
Novartis Ag |
The use of a splicing modulator for a treatment slowing progression of huntington's disease
|
|
AU2021354760A1
(en)
|
2020-09-30 |
2023-05-11 |
Biomarin Technologies B.V. |
Antisense oligonucleotides targeting the exon 51 of dystrophin gene
|
|
TW202304446A
(zh)
|
2021-03-29 |
2023-02-01 |
瑞士商諾華公司 |
剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
|
|
WO2023034870A2
(en)
|
2021-09-01 |
2023-03-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing dmpk expression
|
|
AR128918A1
(es)
|
2022-03-30 |
2024-06-26 |
Biomarin Pharm Inc |
Oligonucleótidos que omiten el exón 51 de distrofina y sus aplicaciones
|
|
EP4702143A2
(en)
|
2023-04-24 |
2026-03-04 |
BioMarin Pharmaceutical Inc. |
Compositions and methods for treating stxbp1 disorders
|
|
WO2024233303A1
(en)
|
2023-05-05 |
2024-11-14 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
WO2026077951A1
(en)
|
2024-10-07 |
2026-04-16 |
Vico Therapeutics B.V. |
Improved aon for rna editing
|